Holen Sie sich die Stockscreener-App
59.81
0.25%
0.20
Schlusskurs vom Vortag:
$59.61
Offen:
$59.95
24-Stunden-Volumen:
95,192
Relative Volume:
0.05
Marktkapitalisierung:
$11.70B
Einnahmen:
$4.08B
Nettoeinkommen (Verlust:
$32.48M
KGV:
427.21
EPS:
0.14
Netto-Cashflow:
$16.80M
1W Leistung:
-4.63%
1M Leistung:
-0.88%
6M Leistung:
-27.42%
1J Leistung:
+9.91%
1-Tages-Spanne:
$59.07
$60.07
1-Wochen-Bereich:
$59.07
$62.87
52-Wochen-Spanne:
$52.81
$83.95
Incyte Corp Stock (INCY) Company Profile
Firmenname
Incyte Corp
Sektor
Branche
Telefon
(302) 498-6700
Adresse
1801 AUGUSTINE CUT-OFF, WILMINGTON, DE
Vergleichen Sie INCY mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
INCY
Incyte Corp
|
59.80 | 11.70B | 4.08B | 32.48M | 16.80M | 0.14 |
|
VRTX
Vertex Pharmaceuticals Inc
|
443.20 | 129.44B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
562.77 | 61.42B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ARGX
Argen X Se Adr
|
624.80 | 38.44B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
271.56 | 33.29B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ONC
Beigene Ltd Adr
|
235.18 | 26.95B | 3.81B | -644.79M | -669.77M | -6.24 |
Incyte Corp Stock (INCY) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-03-18 | Herabstufung | Guggenheim | Buy → Neutral |
| 2025-03-18 | Herabstufung | William Blair | Outperform → Mkt Perform |
| 2024-12-17 | Eingeleitet | UBS | Neutral |
| 2024-10-29 | Hochstufung | BofA Securities | Neutral → Buy |
| 2024-10-01 | Eingeleitet | Wolfe Research | Outperform |
| 2024-09-18 | Herabstufung | Truist | Buy → Hold |
| 2024-07-02 | Herabstufung | BMO Capital Markets | Market Perform → Underperform |
| 2024-05-23 | Eingeleitet | Deutsche Bank | Hold |
| 2024-04-23 | Eingeleitet | Cantor Fitzgerald | Neutral |
| 2024-02-23 | Eingeleitet | Jefferies | Buy |
| 2024-02-14 | Herabstufung | JMP Securities | Mkt Outperform → Mkt Perform |
| 2023-12-13 | Hochstufung | Leerink Partners | Market Perform → Outperform |
| 2023-12-04 | Hochstufung | Guggenheim | Neutral → Buy |
| 2023-11-21 | Herabstufung | Goldman | Buy → Neutral |
| 2023-07-25 | Eingeleitet | Citigroup | Buy |
| 2023-05-04 | Herabstufung | BofA Securities | Buy → Neutral |
| 2023-04-10 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2023-03-24 | Hochstufung | SVB Securities | Underperform → Market Perform |
| 2023-01-31 | Eingeleitet | Piper Sandler | Overweight |
| 2022-08-03 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2022-08-03 | Herabstufung | Guggenheim | Buy → Neutral |
| 2022-07-28 | Eingeleitet | Wells Fargo | Equal Weight |
| 2022-02-09 | Herabstufung | SVB Leerink | Mkt Perform → Underperform |
| 2022-01-18 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
| 2021-11-19 | Eingeleitet | BMO Capital Markets | Market Perform |
| 2021-07-20 | Hochstufung | The Benchmark Company | Hold → Buy |
| 2021-02-10 | Herabstufung | SVB Leerink | Mkt Perform → Underperform |
| 2021-01-07 | Eingeleitet | Truist | Buy |
| 2021-01-04 | Hochstufung | Guggenheim | Neutral → Buy |
| 2020-06-16 | Eingeleitet | The Benchmark Company | Hold |
| 2020-05-06 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2020-04-29 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2020-04-01 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2020-03-24 | Fortgesetzt | William Blair | Outperform |
| 2020-03-13 | Hochstufung | BofA/Merrill | Neutral → Buy |
| 2020-02-04 | Fortgesetzt | BofA/Merrill | Neutral |
| 2020-01-03 | Bestätigt | BMO Capital Markets | Market Perform |
| 2020-01-03 | Herabstufung | Mizuho | Buy → Neutral |
| 2020-01-02 | Herabstufung | Guggenheim | Buy → Neutral |
| 2019-10-03 | Eingeleitet | Mizuho | Buy |
| 2019-09-12 | Eingeleitet | BMO Capital Markets | Market Perform |
| 2019-09-05 | Hochstufung | JMP Securities | Mkt Perform → Mkt Outperform |
| 2019-09-05 | Fortgesetzt | Morgan Stanley | Equal-Weight |
| 2019-09-05 | Hochstufung | Oppenheimer | Perform → Outperform |
| 2019-05-21 | Eingeleitet | Credit Suisse | Neutral |
| 2019-05-03 | Herabstufung | Barclays | Overweight → Equal Weight |
| 2019-04-11 | Eingeleitet | Stifel | Hold |
| 2019-04-03 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2019-01-24 | Hochstufung | William Blair | Mkt Perform → Outperform |
Alle ansehen
Incyte Corp Aktie (INCY) Neueste Nachrichten
Chronic Hand Eczema Pipeline 2025: FDA Approvals, Therapies, - openPR.com
Novartis, Incyte Settle Drug Royalty Fight On Eve Of Trial - Law360
Incyte expects minimal tariff hit, lifts blood cancer drug's 2025 forecast - MSN
Polycythemia vera Market: Epidemiology, Therapies, - openPR.com
Alopecia Areata Pipeline 2025: FDA Updates, Therapy Innovations, and Clinical Trial Landscape Analysis by DelveInsight | Pfizer, Legacy Healthcare, AnaptysBio, Eli Lilly and Company, Incyte Corp - Barchart.com
Incyte to Present at Upcoming Investor Conference - Business Wire
Incyte (INCY) Target Price Raised Following Strong Q1 Performanc - GuruFocus
9 Analysts Have This To Say About IncyteIncyte (NASDAQ:INCY) - Benzinga
Incyte (INCY) Target Price Raised Following Strong Q1 Performance | INCY Stock News - GuruFocus
Incyte (INCY) Receives Adjusted Price Target from TD Cowen | INC - GuruFocus
BofA Boosts Incyte (INCY) Price Target Following Q1 Results | IN - GuruFocus
Incyte (INCY) Target Price Raised by Wells Fargo Despite Mixed R - GuruFocus
Steroid Refactory Acute Graft-Versus-Host Disease Market Growth Projections 2023-2032: DelveInsight Analysis | MaaT Pharma, Medac GmbH, AltruBio Inc., Incyte Corporation - Barchart.com
Incyte Corporation (NASDAQ:INCY) Q1 2025 Earnings Call Transcript - Insider Monkey
Incyte: Q1 Earnings Snapshot - CT Insider
Incyte Corp (INCY) Q1 2025 Earnings Call Highlights: Robust Reve - GuruFocus
Incyte Corp (INCY) Q1 2025 Earnings Call Highlights: Robust Revenue Growth and Strategic ... - Yahoo Finance
Incyte to Showcase Latest Oncology Advancements at 2025 ASCO Meeting - MSN
Earnings call transcript: Incyte Q1 2025 beats expectations, stock rises - Investing.com
BofA raises Incyte stock price target to $89, maintains Buy rating - Investing.com
Earnings call transcript: Incyte Q1 2025 beats expectations, stock rises By Investing.com - Investing.com Canada
INCY Q1 Earnings & Revenues Beat Estimates on Higher Product Sales - The Globe and Mail
Incyte Reports 2025 First Quarter Financial Results and Provides Updates on Key Clinical Programs - BioSpace
Incyte Corp Raises Jakafi Sales Forecast Following Strong Performance - Finimize
Incyte (INCY) Surpasses Q1 Revenue Expectations, Driven by Key P - GuruFocus
Incyte Corp reports results for the quarter ended March 31Earnings Summary - TradingView
Incyte Q1 2025 slides: 26% product revenue growth, Jakafi guidance raised - Investing.com
Incyte Corp (INCY) Q1 2025 Earnings: EPS of $0.80 Beats Estimate, Revenue Surges to $1.053 Billion - GuruFocus
Incyte Reports 2025 First Quarter Financial Results and Provides Updates on Key Clinical Programs | INCY Stock News - GuruFocus
Incyte Q1 Results Top Estimates - Nasdaq
Incyte (INCY) Surpasses Q1 Revenue Expectations, Driven by Key Products | INCY Stock News - GuruFocus
Incyte earnings beat by $0.12, revenue topped estimates - Investing.com
Incyte Reports 2025 First Quarter Financial Results - TradingView
Incyte (INCY) Set to Announce Q1 Earnings, Analysts Cautious - GuruFocus
Incyte (INCY) Q1 Earnings Report Preview: What To Look For - Barchart.com
Incyte to Highlight Early-Stage Oncology Data at American Associ - GuruFocus
Incyte to Highlight Early-Stage Oncology Data at American Association for Cancer Research Annual Meeting 2025 - Business Wire
4Q24 earnings stir biopharma stocks, leading to mixed performance - BioWorld MedTech
Incyte to Showcase New Data from its Oncology Portfolio at 2025 American Society of Clinical Oncology (ASCO) Annual Meeting - BioSpace
Incyte to Showcase New Data from its Oncology Portfolio at 2025 - GuruFocus
Incyte Gears Up to Report Q1 Earnings: Here's What You Should Know - Yahoo Finance
Incyte (INCY) Reports Next Week: Wall Street Expects Earnings Growth - MSN
Finanzdaten der Incyte Corp-Aktie (INCY)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.86%
0.17%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):